

## References

I-117

1. Chiavenna S, Jaworski J, Vendrell A. State of the art in anti-cancer mAbs. *J Biomed Sci*, 2017;24(1):15.
2. Moretto R, Cremolini C, Rossini D, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. *Oncologist*. 2016;21(8):988-94.
3. Kohne CH, Karthaus M, Mineur L, et al. Impact of primary tumor location and early tumor shrinkage on outcomes in patients with RAS wild-type metastatic colorectal cancer following first-line FOLFIRI plus panitumumab. *Drugs RD*. 2019;19(3):267-275.
4. Pietrantonio F, Fuca G, Rossini D, et al. FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer: A propensity score-based analysis. *Oncologist*. 2021;26(4):302-309.
5. Terazawa T, Kato T, Goto M, et al. Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable RAS wild-type colorectal cancer: *Oncologist*. 2021;26(1):17.
6. Rivera F, Karthaus M, Hecht JR, et. al. Final analysis of the randomised PEAK trial: Overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. *Int J Colorectal Dis*. 2017;32(8):1179-1190.
7. Panitumumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 26, 2014.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Panitumumab.
9. Micromedex DrugDex Compendium®. 2024.Panitumumab.
10. National Comprehensive Cancer Network (NCCN). Panitumumab. NCCN Drugs & Biologics Compendium®. 2024.
11. Vectibix® (panitumumab), injection for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 08/2021.